Table 2.

Univariate Analysis and Multivariate analysis of the Correlation Between Clinicopathological Parameters and Survival of Patients With Gastric Cancer

Clinicopathological Parameters	Cumulative Survival Rates, %		Mean Survival Time, mo	Univariate Analysis			Multivariate analysis
	3-Year	5-Year		HR	95% CI	P	HR	95% CI	P
Gender
Male	38	22	37.49	1.000	reference
Female	37	23	35.28	1.106	0.836–1.463	0.479
Age
< 60	50	29	45.15	1.000	reference	1.000	reference
≥ 60	23	14	26.32	1.91	1.458–2.523	< 0.001	1.791	1.327–2.417	< 0.001
Location of tumor
Cardia	69	15	48.23	1.000	reference	1.000	reference
Body	26	13	26.53	1.949	1.032–3.680	< 0.05	1.665	0.847–3.275	0.140
Antrum	41	28	40.95	1.189	0.640–2.207	0.584	1.185	0.617–2.277	0.610
Tumor size, cm
< 5	43	27	40.70	1.000	reference	1.000	reference
≥ 5	30	16	31.04	1.382	1.049–1.820	< 0.05	0.821	0.606–1.111	0.202
Depth of invasion
T1-T2	80	65	70.03	1.000	reference	1.000	reference
T3-T4	29	14	29.94	3.824	2.438–5.998	< 0.001	1.803	1.100–2.953	< 0.05
Stages
I–II	49	34	47.33	1.000	reference	1.000	reference
III–IV	33	17	31.69	1.941	1.219–3.088	< 0.01	1.130	0.765–1.669	0.539
Differentiation
Well and moderate	42	27	41.15	1.000	reference	1.000	reference
Poorly and not	33	17	32.06	1.358	1.033–1.785	< 0.05	0.957	0.662–1.382	0.814
Lymph node metastases
0	77	67	70.67	1.000	reference	1.000	reference
≥1	29	12	29.18	4.285	2.725–6.738	< 0.001	2.965	1.777–4.948	< 0.001
Metastases to other organs
Present	7	7	18.93	1.000	reference	1.000	reference
Absent	40	23	37.87	2.245	1.297–3.884	< 0.01	2.277	1.223–4.240	< 0.01
UHRF1 expression
−	64	38	52.26	1.000	reference	1.000	reference
+	45	30	43.37	1.287	0.849–1.951	0.235	1.421	0.920–2.194	0.113
++	28	13	28.33	2.164	1.431–3.273	< 0.001	1.711	1.093–2.680	< 0.05
+++	11	6	20.71	3.085	1.8905.035	< 0.001	2.553	1.506–4.327	< 0.001

CI indicates confidence interval; HR, hazard ratio.